The board overhaul introduces execution risk despite strong incoming director credentials. Watch for the Q1 2026 10-Q (due May 2026) for full financials and any strategic pivot under new leadership. The non-independent Chairman nomination is unusual and may raise governance concerns with institutional investors.
Price Chart
Executive Summary
TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly above the $18.5M consensus, but the filing is dominated by a near-total board overhaul: Chairman Doug Evans and three other directors are resigning, replaced by four new directors including a non-independent Chairman nominee. The board refresh, while bringing experienced MedTech executives, introduces uncertainty about strategic direction and governance stability.
Key Financial Metrics
Key Facts
- Preliminary Q1 2026 revenue of ~$19.0M, vs $18.5M consensus and prior Q1 guidance of ~$18.5M
- Chairman Doug Evans and three other directors (Kurt Azarbarzin, Vince Burgess, Federica O'Brien) resigning effective after 2026 Annual Meeting
- Joseph Capper (CEO of MiMedx) nominated as Class I director and proposed as Chairman — not expected to qualify as independent
- Three new directors appointed: Guido Neels (EW Healthcare), Guy Nohra (Alta Partners), Paul Thomas (Prominex CEO) — all deemed independent
- Board refresh follows prior Q4 2025 earnings beat (EPS -$0.17 vs -$0.19 consensus) and 18% YoY revenue growth
- Company guided 2026 revenue growth of at least 8% in March 2026 earnings call
Financial Impact
Preliminary Q1 2026 revenue ~$19.0M, ~2.7% above $18.5M consensus; no EPS or profitability data provided
Risk Factors
- Board instability and governance concerns with non-independent Chairman
- Preliminary revenue is unaudited and subject to revision
- Company remains unprofitable with $38.8M net loss in FY2025 and $55.7M in long-term debt
- Historical model performance on TELA shows poor directional accuracy (0% win rate at T+20)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-053102 |
| Document: 0001104659-26-053102-index-headers.html | 0001104659-26-053102 |
| Document: 0001104659-26-053102-index.html | 0001104659-26-053102 |
| Document: 0001104659-26-053102.txt | 0001104659-26-053102 |
| 8-K Data (Synthetic) | 0001104659-26-053102 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $0.7380 $1.24 | ▲ +68.02% | ▲ +68.21% | $1.15 (+55.83%) |
Aug 10, 2026 7w ago | 8-K | $0.7900 $0.9113 | ▼ −15.35% | ▼ −16.41% | $1.15 (−45.57%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.15 (+33.72%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.15 (+33.72%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.15 (+33.72%) |
Jun 11, 2026 16w ago | 3 | $0.8600 $0.8470 | ▼ −1.51% | ▼ −3.29% | $1.15 (+33.72%) |
May 12, 2026 20w ago | 8-K | $0.9600 $0.9120 | ▼ −5.00% | ▼ −4.39% | $1.15 (+19.79%) |
May 12, 2026 20w ago | Press Release | $0.9600 $0.9120 | ▲ +5.00% | ▲ +4.39% | $1.15 (−19.79%) |
Apr 30, 2026 22w ago | 8-K | $0.9890 $0.9000 | ▼ −9.00% | ▼ −14.28% | $1.15 (+16.28%) |
Apr 21, 2026 23w ago | Press Release | $0.6250 $0.8600 | ▲ +37.60% | ▲ +34.43% | $1.15 (+84.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access